Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro

Sorafenib and regorafenib administration is among the preferential approaches to treat hepatocellular carcinoma (HCC), but does not provide satisfactory benefits. Intensive crosstalk occurring between cancer cells and other multiple non-cancerous cell subsets present in the surrounding microenvironm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Dituri, Francesco, Scialpi, Rosanna, Schmidt, Tannin A., Frusciante, Martina, Mancarella, Serena, Lupo, Luigi Giovanni, Villa, Erica, Giannelli, Gianluigi
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7669886/
https://ncbi.nlm.nih.gov/pubmed/33199679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-03180-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados